Eli Lilly’s Jaypirca (pirtobrutinib) has been shown to be superior to Johnson & Johnson (J&J) and AbbVie’s star Bruton's ...

Jaypirca led to better response rates than Imbruvica in some previously treated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

Eli Lilly (LLY) has been actively progressing its pharmaceutical offerings and forging new alliances, as recent product ...

Pirtobrutinib shows promising results in treating CLL, outperforming ibrutinib in a pivotal phase 3 trial, paving the way for ...

This survey serves as a call to action for producers, lawmakers, and educators alike to bridge the knowledge gap and meet the rising demand for cannabis that not only meets minimum safety standards, ...

AbbVie shares promising phase 3 results for Rinvoq in treating severe alopecia areata, with significant hair regrowth ...

CLL-314 trial compared the efficacy and safety of pirtobrutinib with ibrutinib in adults with CLL/SLL who were treatment-naïve or who were previously treated and were BTK inhibitor-naïve.

Eisai (OTCPK:ESALF) and Eli Lilly (NYSE:LLY) on Wednesday announced data from long-term extension studies for their ...